Isavuconazole as Primary Antifungal Prophylaxis in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome: An Open-label, Prospective, Phase 2 Study

BACKGROUND: Mold-active primary antifungal prophylaxis (PAP) is routinely recommended in neutropenic patients with newly diagnosed acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS) undergoing remission-induction chemotherapy (RIC). Isavuconazole (ISAV) is an extended spectrum...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Infect Dis
Main Authors: Bose, Prithviraj, McCue, David, Wurster, Sebastian, Wiederhold, Nathan P, Konopleva, Marina, Kadia, Tapan M, Borthakur, Gautam, Ravandi, Farhad, Masarova, Lucia, Takahashi, Koichi, Estrov, Zeev, Yilmaz, Musa, Daver, Naval, Pemmaraju, Naveen, Naqvi, Kiran, Rausch, Caitlin R, Marx, Kayleigh R, Qiao, Wei, Huang, Xuelin, Bivins, Carol A, Pierce, Sherry A, Kantarjian, Hagop M, Kontoyiannis, Dimitrios P
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2020
Assuntos:
Major Articles and Commentaries
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8130026/
https://ncbi.nlm.nih.gov/pubmed/32236406
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/cid/ciaa358
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados